Interim report 3 Quarter 2010 NattoPharma ASA

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)


New direction with a new Board of Directors and management
In an extraordinary general meeting October 11th 2010, a new Board of Directors was elected based on the company's challenging situation. Mr. Peter Carlsson is appointed CEO. The new CEO, supported by the board of directors, has outlined a new marketing and sales strategy. There is a considerable interest in vitamin K2 in the market, and the company sees significant potential in NattoPharma's proprietary product MenaQ7® base on the company's new strategy. 

Extraordinary General meeting
The company reports a negative equity and the company's financial position is problematic. The Board aims to carry out share issue in the range of NOK 15 to 25 million in 2011. The company will shortly summon for an extraordinary general meeting where also the election of new auditor will take place.

Lower than expected revenues in the 3rd quarter 2010
Sales in the 3rd quarter equalled NOK 1.8 million. This is considerably less than expected. The Earnings before tax as per September 30th 2010 is improved compared to the same period in 2009, and the company's gross margin is also improved. The implementation of new source created challenges, which resulted in NattoPharma for a longer period of the 3rd quarter not being able to supply material.

For further information, please contact:
Mr. Ragnvald Holm Lie,
Mobile phone: +47 900 71 532
Chairman of the Board


About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links